Navigation Links
Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
Date:7/17/2012

p>- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene for the countries covered.

Table of Contents1 Table of Contents1 Table of Contents 51.1 List of Tables 61.2 List of Figures 72 Pricing and Reimbursement in Oncology - Introduction 83 Pricing and Reimbursement in Oncology - Overview 93.1 Development of Oncology Drugs 123.2 Market Access and the Role of Health Economics in Cancer Drugs 133.2.1 Regulation of Cancer Drugs in Europe 133.2.2 Hospital Budgets and Patient Access to Drugs 133.2.3 Payers Managing Influx of New Therapies through Innovative Strategies 143.2.4 Risk Sharing Agreements in the US Vis-à-vis Europe 153.3 Difference in Reimbursement for Oncology Drugs between the US and Europe 153.4 Rationalizing Costs in the US 154 Pricing and Reimbursement in Oncology - The US 164.1 Introduction 164.2 Regulatory Bodies 174.3 Trends 184.3.1 Oncology Practice and Expenditure in the US 184.3.2 Expenditure on Cancer Care Until 2020 - Costs May Increase by 27% from 2010 184.3.3 Reimbursement of Prescription Drugs - Oncology Falls under Tier Four 244.3.4 Strategies to Control Healthcare Spending 244.3.5 Oral Targeted Chemotherapeutics are the Next Paradigm in Cancer Care 254.3.6 Reimbursement Issues in Oral Chemotherapeutics 254.3.7 Oral Chemotherapy Parity Act 265 Pricing and Reimbursement in Oncology - Top Five Countries of Europe 275.1 Italy 275.1.1 Introduction 275.1.2 Regulatory Bodies 285.1.3 Trends 295.2 Spain 315.2.1 Introduction 315.2.2 Regulatory Bodies 315.2.3 Trends 325.3 Germany 345.3.1 Introduction 345.3.2 Regulatory Bodies 355.3.3 Trends 375.4 France 395.4.1 Introduction 395.4.2 Regulatory Bodies 415.4.3 Trends 435.5 The UK 475.5.1 Introduction 475.5.2 Regulatory Bodies 485.5.3 Trends 506 Pricing and Reimbursement in Oncology - Japan 556.1 Introduction 556.2 Regulatory Bodies 576.3 Trends 586.3.1 Fee Changes for the Elderly in Japan S
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
2. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
3. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
4. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
5. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
6. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
7. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
8. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
9. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
10. Early Birds Save Up to $600 on Asian Biotech and Pharmaceutical Conferences
11. Ampio Pharmaceuticals Announces Proposed Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
(Date:5/20/2013)...  Rhythm announced today the presentation of results from ... gastroparesis symptoms among diabetic patients in the U.S. than ... patients with both type 1 and type 2 diabetes, ... the more common type 2 disease. ... Professor of Medicine at Harvard Medical School and Director ...
Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
(Date:5/20/2013)... University of Southampton has shown that blind and visually ... to that used by bats and dolphins, to determine ... is published in the journal Hearing Research , ... could help blind people with spatial awareness and navigation. ... impairment and how to optimise echolocation ability in order ...
(Date:5/20/2013)... 6Webs.com is the leading supplier of ... 6Webs.com recently completed their assessments of the top alarm ... annually and the top home security system companies are ... technology, equipment and warranties to mention a few. ... team completed the home security reviews, numerous people claimed ...
(Date:5/20/2013)... Dermatologists are saying that new federally mandated labeling ... choices when it comes to products that provide ... required by the U.S. Food and Drug Administration ... will protect against skin cancer in addition to ... a sunscreen is water-resistant, according to the American ...
(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...
(Date:5/20/2013)... Researchers at Lund University in Sweden have mapped ... atherosclerotic disease. No studies have previously examined whether ... study looked at coronary heart disease, ischemic stroke, ... in individuals whose siblings and parents have suffered ... showed that heredity is highest for atherosclerosis of ...
Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4
... MKL ) reported diluted net loss per share ... to diluted net income per share of $9.26,for the ... was $2.63 for the,nine months ended September 30, 2008 ... the same period of 2007. The results for both ...
... more targeted prevention efforts, researcher says , , TUESDAY, Nov. 4 ... Hispanics in the United States, a new study shows. , ... a type of beverage that is more associated with risky ... developed to target that beverage and that type of drinking," ...
... HAVEN, Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin ... on Thursday, November 6, 2008 to,discuss its 2008 third ... 8:30 a.m. Eastern Time., To participate in the ... 213-8858 for international callers), at least 15 minutes,before the ...
... 4, 2008 Proactive measures can reduce hip fracture rates ... as 50 percent -- among those at risk, according to ... was published online on November 3 by The Journal ... , The largest study of its kind, the five-year study ...
... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...
... (Nasdaq: IRIX ) today reported financial results for ... the third quarter of 2008 was $12.0 million, an ... quarter of 2007. The,Company recorded net loss of $0.2 ... of 2008, an improvement over the net loss of ...
Cached Medicine News:Health News:Markel Reports Third Quarter and Nine-Month Results 2Health News:Markel Reports Third Quarter and Nine-Month Results 3Health News:Markel Reports Third Quarter and Nine-Month Results 4Health News:Study Shows Hispanics Prefer Beer 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:Healthy bones program reduces hip fractures by 37 percent 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 3Health News:IRIDEX Reports Third Quarter 2008 Financial Results 2Health News:IRIDEX Reports Third Quarter 2008 Financial Results 3Health News:IRIDEX Reports Third Quarter 2008 Financial Results 4Health News:IRIDEX Reports Third Quarter 2008 Financial Results 5Health News:IRIDEX Reports Third Quarter 2008 Financial Results 6
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
Medicine Products: